Item 1. Business
Company Overview
Encision Inc. (“Encision”, “we”,
“us”, “our” or the “Company"), a medical device company based in Boulder, Colorado, has developed and
markets innovative technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. We believe that our
patented Active Electrode Monitoring (AEM®) Surgical Instruments are changing the marketplace for electrosurgical devices and laparoscopic
instruments by providing a solution to a well-documented hazard unique to laparoscopic surgery.
We address market opportunities created by the increase
in minimally-invasive surgery (“MIS”) and surgeons’ use of electrosurgery devices in these procedures. The product opportunity
exists in that monopolar electrosurgery instruments used in laparoscopic procedures provide excellent clinical results, but are also susceptible
to causing inadvertent collateral tissue damage outside the surgeon’s field of view. The risk of unintended electrosurgical burn
injury to the patient in laparoscopic surgery has been well documented. This risk poses a threat to patient safety, including the risk
of death, and creates liability exposure for surgeons and hospitals, and increased and preventable readmissions. Our technology helps
to reduce hospital risk and liability.
Our patented AEM technology provides surgeons with
the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures, while preventing stray electrosurgical energy
that can cause complications and even death. AEM Surgical Instruments are equivalent to conventional instruments in size, shape, ergonomics
and functionality, but they incorporate a proprietary shield and electrically connect to an Active Electrode Monitor to dynamically and
continuously monitor the flow of electrosurgical current, thereby preventing patient injury from stray monopolar energy. With our “shielded
and monitored” instruments, surgeons are able to perform electrosurgical procedures more safely, effectively and economically than
is possible using conventional instruments.
AEM technology has been recommended and endorsed by
sources from many groups involved in MIS. Surgeons, nurses, biomedical engineers, the medicolegal community, malpractice insurance carriers
and electrosurgical device manufacturers advocate the use of AEM technology. In May 2020, the Food and Drug Administration issued a Safety
Communication that stated that, "In addition to serving as an ignition source, monopolar energy use can directly result in unintended
patient burns from capacitive coupling and intra-operative insulation failure.”
Business Highlights
Proprietary, Patented Technology
We have developed and launched patented AEM Surgical
Instruments and Monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. We have been issued 16
unexpired patents relating to AEM technology from the United States Patent and Trademark Office, each encompassing multiple claims, and
which have between one and seventeen years remaining. We also have patents relating to AEM technology issued in Europe, Japan, Canada
and Australia.
Technology Solves a Well Documented Risk in Minimally Invasive Surgery
MIS offers significant benefits for patients by reducing
trauma, hospital stays, recovery times and medical costs. However, these benefits have not been achieved without the emergence of new
risks. The risk of unintended tissue damage from stray electrosurgical energy has been well documented. Such injuries can be especially
troubling given that often these injuries are out of the field of view, can go unrecognized at the time of surgery, and can lead to a
cascade of adverse events, including death. Our patented AEM technology eliminates the risk of stray electrosurgical burns in MIS while
providing surgeons with the tissue effects they desire.
Product Line has been Developed and Launched
Our AEM Surgical Instruments and Monitors have been
engineered to provide a seamless transition for surgeons switching from conventional laparoscopic instruments. AEM technology has been
integrated into instruments that have the same look, feel and functionality as conventional instruments that surgeons have been using
for years. The AEM product line encompasses a full range of instrument sizes, types and styles favored by surgeons. While always quality-centric,
we added a new level of customer-centricity with increased marketing focus on our reposable AEM EndoShield® 2 Burn Protection System
(“EndoShield 2”). The EndoShield 2 can be used for a number of surgical procedures without reprocessing, can easily be used
in any OR room with all prevalent electrosurgical generators, and eliminates a significant barrier to adoption. Thus, hospitals can make
a complete and smooth conversion to our product line, thereby advancing patient safety in MIS.
Emerging as a Standard of Care
We believe that AEM technology is following a similar
path as previous technological developments in surgery. Throughout the history of electrosurgery, companies that have developed significant
technological breakthroughs in patient safety have seen their technologies become widely used. As with “Isolated” electrosurgical
generators in the 1970s and with “REM” technology in the 1980s, AEM technology is receiving the broad endorsements that drove
these previous new technologies to becoming a standard of care. We believe that it is possible to follow a course similar to that of pulse
oximetry in becoming a standard of care. Our proprietary AEM technology enhances patient safety in MIS, especially in light of laparoscopic
instruments being in closer proximity with single-port and reduced-port approaches. As a result, knowledgeable clinicians are now advocating
AEM technology’s use.
Developing Distribution Network is Advancing Utilization of AEM Technology
Our AEM technology, in the hands of a sales network
with broad access to the surgery marketplace, will help to increase utilization and market share. Historically, our sales and marketing
efforts have been hindered by our small size and limited distribution channels. While these limitations continue, we improved our sales
network which provided new hospital accounts with AEM technology in our fiscal year ended March 31, 2023. Our supplier agreements with
Group Purchasing Organizations (“GPOs”) and other key hospitals systems are beginning to expose more hospitals to the benefits
of our AEM technology. During the year ended March 31, 2020, our proprietary patient safety technology was recognized by the U.S. Department
of Veterans Affairs and provides us with the opportunity to market our instruments and monitors into VA Medical Centers. The VA is the
largest medical system in the U.S. providing service to more than nine million veterans across more than 1,200 facilities. Also, during
the year ended March 31, 2020, we were awarded a prestigious Vizient Innovative Technology Contract for monopolar surgical instruments
and monitors. Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals,
integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual medical devices
and supplies purchasing volume.
Market Overview
We believe that our patented AEM technology provides
us with marketing leverage toward gaining an increased share, both in terms of penetrations, as well as increasing our impact per procedure
with AEM instrumentation.
In the 1990s, surgeons began widespread use of minimally
invasive surgical techniques. The benefits of MIS are substantial and include reduced trauma for the patient, reduced hospital stay, shorter
recovery time and lower medical costs. With improvements in the surgical laparoscopic camera and in the variety of available instruments,
laparoscopic surgery became popular among general surgeons, gynecologic surgeons and other specialties. Laparoscopy now accounts for a
large percentage of all surgical procedures performed in the United States. Approximately 75% of surgeons employ monopolar electrosurgery
for laparoscopy according to INTERactive SURVeys. There are over 4.4 million laparoscopic procedures performed annually in the United
States, and this number is increasing annually. (Note: except as otherwise stated, market estimates in this section are as reported by
Patient Safety & Quality Healthcare).
A component of the endoscopic surgery products market
includes laparoscopic hand instruments, including scissors, graspers, dissectors, forceps, suction/irrigation devices, clip appliers and
other surgical instruments of various designs, which provide a variety of tissue effects. Among the laparoscopic hand instruments, approximately
$500 million in sales annually are derived from instruments designed for "monopolar" electrosurgical utility. This market for
laparoscopic monopolar electrosurgical instruments is the market we are targeting with our innovative AEM Surgical Instruments. Our proprietary
AEM product line supplants the conventional “non-shielded, non-monitored” electrosurgical instruments commonly used in laparoscopic
surgery.
When a hospital decides to use our AEM technology,
we make recurring sales to such hospital for replacement instruments. Sales from reusable and disposable AEM products in hospitals represented
over 90% of our sales in the fiscal year ended March 31, 2023, and we expect this sales stream to grow as new hospitals increasingly adopt
AEM technology and existing hospitals increase usage of AEM instrumentation. We also expect to increase the value per procedure delivered
to our customers and, therefore, expect the dollars per procedure to increase. AEM Instruments are competitively priced compared to conventional
laparoscopic instruments.
We aim to further develop the market by continuing
to educate healthcare professionals about the benefits of AEM technology to advance patient safety. We are developing new devices that
integrate AEM technology, which we believe will have high surgeon appeal. We are also working to improve the reach of our sales network
to key decision makers who purchase or recommend the purchase of laparoscopic instruments and electrosurgical devices. We are also pursuing
relationships with selected GPOs, hospital systems and integrated delivery networks to assist in promoting the benefits of AEM technology.
We are seeking increasing international opportunities for AEM technology sales. We estimate sales outside the U.S. to be at least as large
as that of the U.S. market. We are growing our presence in Australia and New Zealand and are seeking a new presence in the Middle East
and Europe. As decisions are made at a system level, our intent is to highlight the clinical, economic and safety benefits of using AEM
technology.
A number of factors are contributing to a decrease in surgical procedures
that take away from top line results. COVID resurgences continued to negatively impact surgical procedure volumes. In addition,
MarketWatch announced that, “A record share of U.S. adults said they or a family member delayed medical care last year due to affordability
issues. According to a Gallup poll, thirty-eight percent of Americans said they or a family member avoided treatment over cost in 2022,
a full 12 percentage points higher than the year prior.” Finally, hospitals are struggling to maintain critical staffing levels
to enable them to keep up with even the decreased demand for procedures.
The Technology
Stray Electrosurgical Burn Injury to the Patient
Electrosurgical technology is a valuable and prevalent
resource for surgeons. Since its introduction in the 1930s, electrosurgical technology has continually evolved and is estimated to be
used in over 75% of all surgeries.
The primary form of electrosurgery, monopolar electrosurgery,
is a standard tool for general surgeons throughout the world. In monopolar electrosurgery, the surgeon uses an instrument (typically scissors,
grasper/dissectors, spatula blades or suction-irrigation electrodes) to deliver electrical current to patient tissue. This “active
electrode” provides the surgeon with the ability to cut, coagulate or ablate tissue as needed during the surgery. With the advent
of MIS procedures, surgeons have continued using monopolar electrosurgery as a primary tool for hemostatic incision, coagulation of bleeding
tissues, excision and ablation. Unfortunately, conventional laparoscopic electrosurgical instruments from competing manufacturers are
susceptible to emitting stray electrical currents during the procedure. This risk is exacerbated by the fact that laparoscopic camera
systems limit the surgical field of view. Ninety percent of the instrument may be outside the surgeon's field of view at any given time
during the surgery.
The dangers of stray energy are twofold. Not only
is there the danger created by the burn injury itself, but there is the compounding danger that the burn will go unnoticed during the
surgery and be allowed to manifest post-operatively as fecal peritonitis or other potentially deadly and devastating outcomes. In many
cases, the surgeon cannot detect stray electrosurgical burns at the time of the procedure because it is out of their field of visualization.
The resulting complication usually presents itself days later in the form of a severe infection or sepsis, which often results in a hospital
readmission and a difficult course of remedial surgeries and prolonged hospital recovery for the patient. This situation has even resulted
in fatalities.
Stray electrosurgical burn injury can result from
two causes – instrument insulation failure and capacitive coupling. Instrument insulation failure can be a common occurrence with
laparoscopic instruments. Conventional active electrodes for laparoscopic surgery are designed with the same basic construction –
a single conductive element and an outer insulation coating. This insulation can fail during the course of normal use during surgery.
One university study found insulation defects in new disposable instruments before they were used or after limited surgical use. It is
also possible for instrument insulation to become flawed during the handling, cleaning and sterilization process. This common insulation
failure can allow electrical currents to "spark" from the instrument to unintended and unseen tissue with potentially serious
consequences for the patient, such as bowel perforations. Four different studies indicate that the insulation failure rate in reusable
instruments can be as high as one in five. Capacitive coupling is another way stray electrosurgical energy can cause unintended burns
during laparoscopy. Capacitive coupling is an electrical phenomenon that occurs when current is induced from the instrument to nearby
tissue or another instrument despite intact insulation. This potential for capacitive coupling is present in all laparoscopic surgeries
that utilize monopolar electrosurgery devices and are likely to occur outside the surgeon’s field of view.
Conventional, “non-shielded, non-monitored”
laparoscopic instruments are susceptible to causing unintended, unseen burn injuries to the patient in MIS. Instrument insulation failure
and capacitive coupling are the primary causes of stray electrosurgical burns in laparoscopy and are the two events over which the surgical
team has traditionally had no control. Although alternative forms to monopolar electrosurgery energy exist, these alternative energies
tend to be less effective, take longer to achieve the desired surgical effect and are costlier.
Encision’s AEM Surgical Instruments
AEM technology eliminates the risk of stray electrical
energy caused by instrument insulation failure and capacitive coupling, and thus prevents unintended burn injuries to patients.
AEM Surgical Instruments are an innovative solution
to stray electrosurgical burns in laparoscopic surgery and are designed with the same look, feel and functionality as conventional instruments.
They direct electrosurgical energy where the surgeon desires, while continuously monitoring the current flow to prevent stray electrosurgical
energy from instrument insulation failure or capacitive coupling.
Whereas conventional instruments are simply a conductive
element with a layer of insulation coating, AEM Surgical Instruments have a patented, multi-layered design with a built-in “shield,”
a concept much like the third-wire ground in standard electrical cords. The shield in these instruments is electrically connected and
referenced back to an AEM Monitor at the electrosurgical generator. In the event of a harmful level of stray electrical energy, the monitor
shuts down the power at the source, assuring patient safety. If instrument insulation failure should occur, the AEM system, while continually
monitoring the instrument, immediately interrupts monopolar output from the electrosurgical generator and alerts the surgical staff. The
AEM system protects against capacitive coupling by providing a neutral return path for “capacitive” electrical energy. Capacitive
energy is continually drained away from the instrument and away from the patient through the protective shield built into all AEM instruments
and the connected AEM Monitor.
The AEM system consists of shielded 5mm AEM Instruments
and an AEM monitor. The AEM Instruments are designed to function identically to the conventional 5mm instruments that surgeons are familiar
with, but with the added benefit of enhanced patient safety. Our entire line of laparoscopic instruments has the integrated AEM design
and includes the full range of instruments that are common in laparoscopic surgery today. The AEM monitor is compatible with most electrosurgical
generators. AEM Surgical Instruments provide enhanced patient safety, require no change in surgeon technique and are cost competitive.
Thus, conversion to AEM Surgical Instruments is easy and economical.
Historical Perspective
We were organized
as a Colorado corporation in 1991 and spent several years developing the AEM monitoring system and protective sheaths to adapt to conventional
electrosurgical instruments. During this period, we conducted product trials and applied for patents with the United States Patent and
Trademark Office and with International patent agencies. Our patents relate to the
basic shielding and monitoring technologies that we incorporate into our AEM products. As of March 31, 2023, we have 16 unexpired United
States patents relating to specific implementations of shielding and monitoring in instruments and continue to add patents as we further
develop our proprietary technology and its applications.
As we evolved, it was clear to us that our “active
electrode monitoring” technology needed to be integrated into the standard laparoscopic instrument design. As the development program
proceeded, it also became apparent that the merging of electrical and mechanical engineering skills in the instrument development process
for our patented, integrated electrosurgical instruments was a complex and difficult task. As a result, instruments with integrated AEM
technology were not completed for several years. Prior to offering a full range of laparoscopic electrosurgical instrumentation, it was
difficult for hospitals to commit to the AEM solution, as we did not have adequate comparable surgical instrument options to match surgeon
demand.
With the broad
array of AEM instruments now available, the surgeon has a wide choice of instrument options and does not have to change surgical technique
to use our AEM products. Since conversion to AEM technology is transparent to the surgeon, hospitals
can now universally convert to AEM technology, thus providing all of their laparoscopic surgery patients a higher level of safety. This
development coincides with the continued expansion of independent endorsements for AEM technology. Recommendations from the malpractice
insurance and medicolegal communities complement the broad clinical endorsements that AEM technology has garnered over the past few years,
leading to better awareness for the benefits of the technology.
Products
We produce and market a full line of AEM Instruments,
which are “shielded and monitored” to prevent stray electrosurgical burns from insulation failure and capacitive coupling.
Our product line includes a broad range of endo-mechanical instruments (scissors, graspers and dissectors), fixed-tip electrodes and suction-irrigation
electrodes. These AEM Instruments are available in a wide array of reusable and disposable options. Also, we have a line of handles that
are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features. In addition, we market an AEM monitor
product line that is used in conjunction with AEM Instruments. Our AEM EndoShield® 2 Burn Protection System can be used for a number
of surgical procedures without reprocessing, reduces the customer’s cost per use significantly, and eliminates a significant barrier
to adoption. Thus, hospitals can make a complete and smooth conversion to our product line, thereby advancing patient safety in MIS. The
EndoShield 2 integrates our patented AEM technology into a disposable smart cord and eliminates the need for a separate AEM monitor. It
is changing the marketplace for electrosurgical devices and laparoscopic instruments by providing a solution to a well-documented hazard
unique to laparoscopic surgery.
The 2020 introduction of our AEM 2X enTouch®
Scissors (“2X Scissors”) brought new levels of performance and economy to the surgical scissor market by combining the
best in class performance of our enTouch Disposable Scissors with the value and economy of a multi-use device. We believe that our 2X Scissors
will have a significant impact on the disposable laparoscopic scissor market. Our enTouch Disposable Scissors have long been the surgeon
preferred product because of their sharpness and micro-serrations. Our 2X Scissors provide all those benefits at half the cost per
use and reduce hospital waste and the impact on the environment as well. The thermochromic technology integrated into 2X Scissors
lets the hospital know when to replace the scissors with new ones and makes tracking their use simple and easy. 2X Scissors work
with hot AEM dissection and have a price point that makes them suitable for cold dissection as well. 2X Scissors should open new
use segments for us and create an opportunity for customers to standardize on our entire portfolio of Active Electrode Monitoring (AEM®)
products.
Services
On April 20, 2020, we entered into a Master Services
Agreement (“MSA”) with Auris Health, Inc. (“Auris Health”), which is based in Redwood City, CA and a part of Johnson
& Johnson Medical Devices Companies. The MSA (and the initial related Statement of Work thereunder) were effective as of March 3,
2020. Under the MSA, we and Auris Health collaborated on the development of equipment designed to enable the compatibility of our AEM
technology with monopolar instruments produced by Auris Health. The MSA had a term of up to three years, but either party could terminate
the MSA sooner upon 10 business days’ prior written notice. On August 23, 2021, we entered into a Supply Agreement with Auris Health,
Inc. On May 5, 2022, the parties mutually agreed to terminate all of our agreements.
In February 2023, we signed a Proof of Concept Services
Agreement with Vicarious Surgical Inc. (“Vicarious”). The Vicarious robot design intends to maximize visualization, precision,
and control of instruments in robotic-assisted minimally invasive surgery.
Sales and Marketing Overview
We believe that AEM technology can become the standard
of care in laparoscopic surgery worldwide. Our marketing efforts are focused on building awareness by providing technical education for
Health Care Providers on the dangers of stray electrosurgical energy and in providing clinical and economic evidence to substantiate the
value of AEM technology to hospitals, their staff, and their patients. We also leverage relationships with prominent hospitals and surgeons
where AEM Technology has increased their level of patient care and improved their overall surgical outcomes.
In addition, there is increasing public interest in
the reduction of medical errors and the advancement of patient safety. For example, the National Quality Forum and CMS (Centers for Medicare
and Medicaid Services) recognize “patient death or serious disability associated with a burn incurred from any source while being
cared for in a healthcare facility” as a “never-event”. We believe that the credibility and importance of our technology
is complemented by this expanding public interest in advancing patient safety in new CMS Hospital Quality Metrics. The Center for Medicare
and Medicaid Services published its Hospital-Acquired Condition Reduction Program, effective October 1, 2014. At that time, the program
began to levy as much as a 1% penalty on Medicare reimbursements on hospitals in the lower quadrant of performance for selected quality
indicators, including accidental puncture and laceration (“APL”). An example of an APL includes the use of a cautery device
(electrosurgery) or scissors to dissect a tissue plane that errantly causes an injury to underlying bowels.
To cost effectively expand market coverage, we focus
on optimizing our distribution network comprised of direct and independent sales representatives who are managed and directed by our regional
sales managers throughout the United States. In some instances, customers have recognized the patient safety risks inherent in monopolar
electrosurgery and have accepted AEM technology as the way to eliminate those risks. In other instances, we have found selling the concept
behind AEM technology more difficult. This difficulty is due to several factors, including the necessity to make surgeons, nurses and
hospital risk managers aware of the potential for unintended electrosurgical burns (which exists when conventional instruments are used
during laparoscopic monopolar electrosurgery) and the resulting increased patient injury and medicolegal liability exposure. Additionally,
we must contend with the overall lack of single purchasing points in the industry (surgeons, hospital personnel, and value analysis committees
have to be in substantial agreement as to the benefits of new technology), and the resulting need to make multiple sales calls on personnel
with the authority to commit to hospital expenditures. Other challenges include the fact that many hospitals have exclusive contractual
agreements with manufacturers of competing surgical instruments.
Our goal is to optimize a network that has experience
selling into the hospital operating room environment. We believe that improvement in this network offers us the best opportunity to cost
effectively broaden acceptance of our product line and generate increased and recurring sales. Additionally, we are pursuing supplier
agreements with the major selected GPOs, hospital systems and integrated delivery networks.
In addition to the efforts to broaden market acceptance
in the United States, we have contracted with independent distributors in Australia and New Zealand to market our products internationally.
We have achieved Conformité Européene (“CE”) marking for our products so that we may sell into the European
marketplace. The CE marking indicates that a manufacturer has conformed to all of the obligations imposed by European health, safety and
environmental legislation. While CE certification opens up incremental markets in Europe, our distribution options in the European marketplace
are developing, and sales in international markets are small.
We believe that the expanding awareness for AEM technology
through education and the improved sales network of independent representatives will provide the basis for increased sales and continuing
profitable operations. However, these measures, or any others that we may adopt, may not result in increased sales or profitable operations.
Research and Development
We aim to continually expand our AEM Instrument product
line to satisfy the evolving needs of surgeons. For AEM technology to fully become a standard of care, we must satisfy surgeons’
preferred instrument shapes, sizes, styles and functionality with integrated AEM technology. This commitment includes expanding the styles
of electrosurgical instruments available for MIS applications so that the conversion to AEM technology is transparent to surgeons and
does not require significant change in their current surgical techniques. We employ full-time engineers and use independent contractors
from time to time in our research and product development efforts. This group continuously explores ways to broaden and enhance the product
line. Current research and development efforts are focused primarily on line-extension projects to further expand our AEM Instrument product
offering to increase surgeons’ choices and options in laparoscopic surgery. Our research and development expenses were $816,119
in fiscal year 2023 and $918,155 in fiscal year 2022. We expense research and development costs for products and processes as incurred.
Costs that are included in research and development expenses include direct salaries, contractor fees, materials, facility costs and administrative
expenses that relate to research and development.
Manufacturing, Regulatory Affairs
and Quality Assurance
We engage in various manufacturing and assembly activities
at our leased facility in Boulder, Colorado. These operations include disposable scissor inserts manufacturing and assembly of our AEM
Instrument system as well as fabrication, assembly and test operations for instruments, monitors and accessories. We also have relationships
with a number of outside suppliers. Three vendors accounted for approximately 47% of our inventory purchases.
We believe that the use of both internal and external
manufacturing capabilities allows for increased flexibility in meeting our customer delivery requirements and significantly reduces the
need for investment in specialized capital equipment. We have developed multiple sources of supply where possible. Our relationship with
our suppliers is generally limited to individual purchase order agreements supplemented, as appropriate, by contractual relationships
to help ensure the availability and low cost of certain products. All components, materials and sub-assemblies used in our products, whether
produced in-house or obtained from others, are inspected to ensure compliance with our specifications. All finished products are subject
to our quality assurance and performance testing procedures.
As discussed in the section on Government Regulation,
we are subject to the rules and regulations of the United States Food and Drug Administration (“FDA”). Our leased facility
of 28,696 square feet contains approximately 15,100 square feet of manufacturing, regulatory affairs and quality assurance space. The
facility is designed to comply with the Quality System Regulation (“QSR”), as specified in published FDA regulations. Our
latest inspection by the FDA occurred in October 2015.
We achieved CE marking in August 2000, which required
prior certification of our quality system and product documentation. Maintenance of the CE marking status requires periodic audits of
the quality system and technical documentation by our European Notified Body, TUV Rheinland. The most recent audit was completed in February
2022.
Patents, Patent Applications and
Intellectual Proprietary Rights
We have invested heavily in an effort to protect our
valuable technology, and, as a result of this effort, we have been issued 16 unexpired relevant patents that together form a significant
intellectual property position. Our patents relate to the basic shielding and monitoring technologies that we incorporate into our AEM
products. As of March 31, 2023, we have 16 unexpired United States patents relating to specific implementations of shielding and monitoring
in instruments. As of March 31, 2023, there are between one and seventeen years remaining on our AEM patents. We have five patent applications
in process and we have four trademarks.
Our technical progress depends to a significant degree
on our ability to maintain patent protection for products and processes, to preserve our trade secrets and to operate without infringing
the proprietary rights of third parties. Our policy is to attempt to protect our technology by, among other things, filing patent applications
for technology that we consider important to the development of our business. The validity and breadth of claims covered in medical technology
patents involve complex legal and factual questions and, therefore, may be highly uncertain. Even though we hold patented technology,
others might copy our technology or otherwise incorporate our technology into their products.
We require our employees to execute non-disclosure
agreements upon commencement of employment. These agreements generally provide that all confidential information developed or made known
to the individual by us during the course of the individual's employment is our property and is to be kept confidential and not to be
disclosed to third parties.
Competition
The electrosurgical device market is intensely competitive
and tends to be dominated by a relatively small group of large and well-financed companies. We compete directly for customers with those
companies that currently make conventional electrosurgical instruments. Larger competitors include Advanced Surgical Technologies Group
(a division of Medtronic plc) and Ethicon Endo-Surgery (a division of Johnson & Johnson). While we know of no competitor (including
those referenced above) that can provide a continuous solution to stray electrosurgical burns, the manufacturers of conventional (non-monitored,
non-shielded) instruments will resist any loss of market share resulting from the presence of our products in the marketplace. What clearly
differentiates us from the competition is that while competitive technologies may somewhat reduce the risk of stray energy burns, only
AEM Technology completely eliminates it.
We also believe that manufacturers of products based
on alternative technology to monopolar electrosurgery are our competitors. These alternative technologies include other “advanced
energy” technologies such as bipolar electrosurgery, laser surgery and ultrasonic dissector sealers. Leading manufacturers in these
areas include Advanced Surgical Technologies Group, Gyrus/ACMI (a division of Olympus Corporation and a leader in bi-polar electrosurgery),
Lumenis (laser surgery) and Ethicon Endo-Surgery (a division of Johnson and Johnson, manufacturers of the harmonic scalpel). We believe
that monopolar electrosurgery offers substantial competitive, functional and financial advantages over these alternative energy technologies
and will remain the primary tool for the surgeon, as it has been for decades. However, the risk exists that these alternative technologies
may gain greater market share and that new competitive techniques may be developed and introduced.
As mentioned in the Sales and Marketing discussion,
the competitive issues involved in selling our AEM product line do not primarily revolve around a comparison of cost or features, but
rather involve generating an awareness of the inherent hazards of electrosurgery and the potential for injury to the patient. This involves
conceptual selling, rather than just product selling, which results in a longer sales cycle and generally higher sales costs. Independent
endorsements of AEM technology have greatly enhanced the credibility of AEM Instruments. However, our efforts to increase market awareness
of this technology may not be successful, and our competitors may develop alternative strategies and/or products to counter our marketing
efforts.
Many of our competitors and potential competitors
have widely-used products and significantly greater financial, technical, product development, marketing and other resources. In addition
to our direct sales force, we utilize a network of independent distributor representatives in selected areas. In some cases, our options
for independent distribution have conflicting and competing product interests which compromise our ability to make market advances in
certain areas. We may not be able to compete successfully against current and future competitors, and competitive pressures faced by us
may have a material adverse impact on our business, operating results and financial condition.
Government Regulation
Government regulation in the United States and other
countries is a significant factor in the development and marketing of our products and in our ongoing manufacturing, research and development
activities. The FDA regulates us and our products under a number of statutes, including the Federal Food, Drug and Cosmetics Act (the
“FDC Act”). Under the FDC Act, medical devices are classified as Class I, II or III on the basis of the controls deemed necessary
to reasonably ensure their safety and effectiveness. Class I devices are subject to the least extensive controls, as their safety and
effectiveness can be reasonably assured through general controls (e.g., labeling, pre-market notification and adherence to QSR). For Class
II devices, safety and effectiveness can be assured through the use of special controls (e.g., performance standards, post-market surveillance,
patient registries and FDA guidelines). Class III devices (e.g., life-sustaining or life-supporting implantable devices or new devices
which have been found not to be substantially equivalent to legally marketed devices) require the highest level of control, generally
requiring pre-market approval by the FDA to ensure their safety and effectiveness. Our products are Class II devices.
If a manufacturer or distributor of medical devices
can establish that a proposed device is "substantially equivalent" to a legally marketed Class I or Class II medical device
or to a Class III medical device for which the FDA has not required a pre-market approval application, the manufacturer or distributor
may seek FDA marketing clearance for the device by filing a 510(k) pre-market notification. Following submission of the 510(k) notification,
the manufacturer or distributor may not place the device into commercial distribution in the United States until an order has been issued
by the FDA. The FDA's target for issuing such orders is within 90 days of submission, but the process can take significantly longer. The
order may declare the FDA's determination that the device is "substantially equivalent" to another legally marketed device and
allow the proposed device to be marketed in the United States. The FDA may, however, determine that the proposed device is not substantially
equivalent or may require further information, such as additional test data, before deciding regarding substantial equivalence. Any adverse
determination or request for additional information could delay market introduction and have a material adverse effect on our continued
operations. We have received a favorable 510(k) notification for our AEM monitors and AEM Instruments, all of which are designated as
Class II medical devices.
Labeling and promotional activities are subject to
scrutiny by the FDA and, in certain instances, by the Federal Trade Commission. The FDA also imposes post-marketing controls on us and
our products, and registration, listing, medical device reporting, post-market surveillance, device tracking and other requirements on
medical devices. Failure to meet these pervasive FDA requirements or adverse FDA determinations regarding our clinical and preclinical
trials could subject us and/or our employees to injunction, prosecution, civil fines, seizure or recall of products, prohibition of sales
or suspension or withdrawal of any previously granted approvals, which could lead to a material adverse impact on our financial position
and results of operations.
The FDA regulates our quality control and manufacturing
procedures by requiring us and our contract manufacturers to demonstrate compliance with the QSR as specified in published FDA regulations.
The FDA requires manufacturers to register with the FDA, which subjects them to periodic FDA inspections of manufacturing facilities.
If violations of applicable regulations are noted during FDA inspections of our manufacturing facilities or the facilities of our contract
manufacturers, the continued marketing of our products may be adversely affected. Such regulations are subject to change and depend heavily
on administrative interpretations. In October 2015, the FDA conducted a QSR inspection of our facilities. We believe that we have the
internal resources and processes in place to be reasonably assured that we are in compliance with all applicable United States regulations
regarding the manufacture and sale of medical devices. However, if we were found not to be in compliance with the QSR, in the future,
such findings could result in a material adverse impact on our financial condition, results of operations and cash flows.
Sales of medical devices outside of the United States
are subject to United States export requirements and foreign regulatory requirements. Legal restrictions on the sale of imported medical
devices vary from country to country. The time required to obtain approval by a foreign country may be longer or shorter than that required
for FDA approval and the requirements may differ. Our Certificate of Export from the United States Department of Health and Human Services
has expired and we will seek to renew it. However, a specific foreign country in which we wish to sell our products may not accept or
continue to accept the Certificate of Export. Entry into the European Economic Area market also requires prior certification of our quality
system and product documentation. We achieved CE marking in August 2000, allowing a launch into the European marketplace. Maintenance
of the CE marking status requires annual audits of the quality system and technical documentation by our European Notified Body, TUV Rheinland.
The most recent audit was completed in February 2022.
During our March 31, 2020 quarter, we received a letter
from the FDA that contained a questionnaire regarding Stray Energy and how to prevent patient injuries from Stray Energy during
laparoscopic procedures. We provided the FDA with extensive information on burns and our program for eliminating them. A Safety Communication
was released by the FDA on May 29, 2020. It is on the FDA's website at: https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm608637.htm.
The Safety Communication states that, "In addition to serving as an ignition source, monopolar energy use can directly result in
unintended patient burns from capacitive coupling and intra-operative insulation failure. If a monopolar electrosurgical units (ESU) is
used: Do not activate when near or in contact with other instruments.”
Environmental Laws and Regulations
From time to time we receive materials returned from
customers, sales representatives and other sources which are potentially biologically hazardous. These materials are segregated, and disposed
of in accordance with specific procedures that minimize potential exposure to employees. The costs of compliance with these procedures
are not significant. Our operations, in general, do not involve the use of environmentally sensitive materials.
Insurance
We are covered under comprehensive general liability
insurance policies, which have per occurrence and aggregate limits of $1 million and $2 million, respectively, and a $10 million umbrella
policy. We maintain customary property and casualty, workers’ compensation, employer liability and other commercial insurance policies.
Employees
As of March 31, 2023, we employed 31 full-time and
2 part-time individuals, of which 4 full-time and 2 part-time are engaged directly in research, development and regulatory activities,
14 full-time in manufacturing/operations, 7 full-time in marketing and sales, and 6 full-time time in administrative positions. None of
our employees are covered by a collective bargaining agreement, and we consider our relations with our employees to be good.
Available information
Our internet address is www.encision.com. We are not
including the information contained in our website as part of, or incorporating it by reference into, this document. We make available,
free of charge, through our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments
to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after
we electronically file such materials with, or furnish such materials to, the SEC.
Item 1A. Risk Factors
You should carefully consider the risk factors described
below. If any of the following risk factors actually occur, our business, prospects, financial condition or results of operations would
likely suffer. In such case, the trading price of our common stock could fall, resulting in the loss of all or part of your investment.
You should look at all these risk factors in total. Some risk factors may stand on their own. Some risk factors may affect (or be affected
by) other risk factors. You should not assume we have identified these connections. You should not assume that we will always update these
and future risk factors in a timely manner. We are not undertaking any obligation to update these risk factors to reflect events or circumstances
after the date of this report or to reflect the occurrence of unanticipated events.
Among the factors that could cause future results
and financial condition to be materially different from expectations are:
Covid-19. We are monitoring the ongoing
outbreak of Covid-19, and the related mandated precautions to mitigate the spread of the disease, including various business
restrictions and its impact on operations, financial position, cash flow, inventory, supply chains, purchasing trends, customer
payments, the industry in general and its impact on our employees. The impact of the disease and related public health measures is
highly uncertain, cannot be predicted, and will dependent upon future developments. During the 2023 and 2022 fiscal years, our
operations were still significantly negatively impacted by Covid-19. This reduction was primarily due to a significant reduction in
elective surgical procedures due to Covid-19, which reduced demand for our products.
Our products may not be accepted by the market.
The success of our products and our financial condition depends on the acceptance of AEM products by the medical community in commercially
viable quantities during fiscal year 2023 and beyond. We cannot predict how quickly or how broadly AEM products will be accepted by the
medical community. We need to continually educate the marketplace about the potential hazards involved in the use of conventional electrosurgical
products during MIS procedures and the expected benefits associated with the use of AEM products. If we are unsuccessful in educating
the marketplace about our technology and the hazards of conventional instruments, we will not create sufficient demand by hospitals and
surgeons for AEM products and our financial condition, results of operations and cash flows could be adversely affected.
We need to continually develop and train our network
of direct and independent sales representatives and expand our distribution efforts in order to be successful. Our attempts to develop
and train a network of direct and independent sales representatives in the U.S. and to expand our international distribution efforts may
take longer than expected and may result in considerable amounts of retraining effort as the direct and independent sales representatives
change their product lines, product focus and personnel. We may not be able to obtain full coverage of the U.S. by direct and independent
sales representatives as quickly as anticipated. The independent sales representative network has inherent flaws and inefficiencies, which
can include conflicts of interest and competing products. Optimizing the quality of the network and the performance of direct and independent
sales representatives in the U.S. is an ongoing challenge. We may also encounter difficulties in developing our international presence
due to regulatory issues and our ability to successfully develop international distribution options. Our inability to expand our network
of direct and independent sales representatives and optimize their performance could adversely affect our financial results.
We may need additional funding to support our operations.
We were formed in 1991 and have incurred losses of approximately $22 million since that date. We have primarily financed research, development
and operational activities with issuances of our common stock and warrants, the exercise of stock options to purchase our common stock,
loans, and, in some years, by operating profits. For the fiscal year ended March 31, 2023, our cash used in operations was $861,000. At
March 31, 2023, we had cash and equivalents of $182,000. If we are unable to maintain cash flows sufficient to support ongoing operations,
we will need to seek additional financing. There is no assurance that we will be able to raise additional capital on acceptable terms
or at all. If we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our
existing stockholders could be diluted, and these newly issued securities may have rights, preferences or privileges senior to those of
existing stockholders. If we raise additional funds through debt financing, which may involve restrictive covenants, our ability to operate
our business may be restricted. If adequate funds are not available or are not available on acceptable terms, if and when needed, our
ability to fund our operations, our business, results of operations and financial condition could be materially and adversely affected.
.
We may not be able to compete successfully against
current manufacturers of conventional (“unshielded, unmonitored”) electrosurgical instruments or against competitors who manufacture
products that are based on surgical technologies that are alternatives to monopolar electrosurgery. The electrosurgical products market
is intensely competitive. We expect that manufacturers of “unshielded, unmonitored” electrosurgical instruments will resist
any loss of market share that might result from the presence of our “shielded and monitored” instruments in the marketplace.
We also believe that manufacturers of products that are based upon surgical technologies that are alternatives to monopolar electrosurgery
are our competitors. These technologies include bipolar electrosurgery, the harmonic scalpel and lasers. The alternative technologies
may gain market share and new competitive technologies may be developed and introduced. Most of our competitors and potential competitors
have significantly greater financial, technical, product development, marketing and other resources than we do. Most of our competitors
also currently have substantial customer bases in the medical products market and have significantly greater market recognition than we
have. As a result of these factors, our competitors may be able to respond more quickly to new or emerging technologies and changes in
customer requirements or to devote greater resources to the development, promotion and sale of their products. It is possible that new
competitors or new alliances among competitors may emerge and rapidly acquire significant market share. The competitive pressures we face
may materially adversely affect our financial position, results of operations and cash flows, and this may hinder our ability to respond
to competitive threats.
If we do not continually enhance our products and
keep pace with rapid technological changes, we may not be able to attract and retain customers. Our future success and financial performance
will depend in part on our ability to meet the increasingly sophisticated needs of customers through the timely development and successful
introduction of product upgrades, enhancements and new products. These upgrades, enhancements and new products are subject to significant
technological risks. The medical device market is subject to rapid technological change, resulting in frequent new product introductions
and enhancements of existing products, as well as the risk of product obsolescence. While we are currently developing new products and
enhancing our existing product lines, we may not be successful in completing the development of new products or enhancements. In addition,
we must respond effectively to technological changes by continuing to enhance our existing products to incorporate emerging or evolving
standards. We may not be successful in developing and marketing product enhancements or new products that respond to technological changes
or evolving industry standards. We may experience difficulties that could delay or prevent the successful development, introduction and
marketing of those products, and our new products and product enhancements may not adequately meet the requirements of the marketplace
and achieve commercially viable levels of market acceptance. If any potential new products, upgrades, or enhancements are delayed, or
if any potential new products, upgrades, or enhancements experience quality problems or do not achieve market acceptance, or if new products
make our existing products obsolete, our financial position, results of operations and cash flows would be materially adversely affected.
If government regulations change or if we fail
to comply with existing and/or new regulations, we might miss market opportunities and experience increased costs and limited growth.
The research, development, manufacturing, marketing and distribution of our products in the United States and other countries are
subject to extensive regulation by numerous governmental authorities including, but not limited to, the Food and Drug Administration.
Under the Federal Food, Drug and Cosmetic Act, medical devices must receive clearance from the Food and Drug Administration through the
Section 510(k) pre-market notification process or through the lengthier pre-market approval process before they can be sold in the United
States. The process of obtaining required regulatory approvals is lengthy and has required the expenditure of substantial resources. There
can be no assurance that we will be able to continue to obtain the necessary approvals. As part of our strategy, we also intend to pursue
commercialization of our products in international markets. Our products are subject to regulations that vary from country to country.
The process of obtaining foreign regulatory approvals in certain countries can be lengthy and require the expenditure of substantial resources.
We may not be able to obtain necessary regulatory approvals or clearances on a timely basis or at all, and delays in receipt of or failure
to receive such approvals or clearances, or failure to comply with existing or future regulatory requirements would have a material adverse
effect on our financial position, results of operations and cash flows. Tariffs will increase our material costs and, if they are fully
absorbed by us, then they will negatively affect our gross profit margins.
If we fail to comply with the extensive regulatory
requirements governing the manufacturing of our products, we could be subject to fines, suspensions or withdrawals of regulatory approvals,
product recalls, suspension of manufacturing, operating restrictions and/or criminal prosecution. The manufacturing of our products
is subject to extensive regulatory requirements administered by the Food and Drug Administration and other regulatory agencies. Inspection
of our manufacturing facilities and processes can be conducted at any time, without prior notice, by the Food and Drug Administration
and such regulatory agencies. In addition, future changes in regulations or interpretations made by the Food and Drug Administration or
other regulatory agencies, with possible retroactive effect, could adversely affect us. Changes in existing regulations or adoption of
new regulations or policies could prevent us from obtaining, or affect the timing of, future regulatory approvals or clearances. We may
not be able to obtain necessary regulatory approvals or clearances on a timely basis in the future, or at all. Delays in receipt of, failure
to receive such approvals or clearances and/or failure to comply with existing or future regulatory requirements would have a material
adverse effect on our financial position, results of operations and cash flows.
Our current patents, trade secrets and know-how
may not provide a competitive advantage, the pending applications may not result in patents being issued, and our competitors may design
around any patents issued to us. Our success will continue to depend in part on our ability to maintain patent protection for our
products and processes, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties. We have
16 issued U.S. patents on several technologies embodied in our AEM Monitoring system, AEM instruments and related accessories and we have
applied for additional U.S. patents. In addition, we have four issued foreign patents. The validity and breadth of claims coverage in
medical technology patents involve complex legal and factual questions and may be highly uncertain. Also, patents may not protect our
proprietary information and know-how or provide adequate remedies for us in the event of unauthorized use or disclosure of such information,
and others may be able to develop competing technology, independent of such information. There has been substantial litigation regarding
patent and other intellectual property rights in the medical device industry. Litigation may be necessary to enforce patents issued to
us, to protect trade secrets or know-how owned by us, to defend us against claimed infringement of the rights of others or to determine
the ownership, scope or validity of our proprietary rights or those of others. Any such claims may require us to incur substantial litigation
expenses and to divert substantial time and effort of management personnel and could substantially decrease the amount of capital available
for our operations. An adverse determination in litigation involving the proprietary rights of others could subject us to significant
liabilities to third parties, could require us to seek licenses from third parties, and could prevent us from manufacturing, selling or
using our products. The occurrence of any such actual or threatened litigation or the effect on our business of such litigation may materially
adversely affect our financial position, results of operations and cash flows. Additionally, our assessment that a patent is no longer
of value could result in a significant charge against our earnings.
We depend on single source suppliers for certain
of the key components of our products and sub-contractors to provide much of the materials used in the manufacturing of our products.
The loss of a supplier or limitation in supply from existing suppliers could have a material adverse effect on our ability to manufacture
our products until a new source of supply is located. Although we believe that there are alternative suppliers, any interruption in
the supply of key components could have a material adverse effect on us. A sudden increase in customer demand may create a backorder situation
as lead times for some of our critical materials are in excess of 16 weeks. We rely on subcontractors to provide products, either in the
form of finished goods or sub-assemblies that we then assemble and test. While these sub-contractors reduce our total cost of manufacturing,
they may not be as responsive to increased demand as we would be if we had our manufacturing capacity entirely in-house, which may limit
our growth strategy and sales.
The potential fluctuation in future quarterly results
may cause our stock price to fluctuate. We expect that our operating results could fluctuate significantly from quarter to quarter
in the future and will depend upon a number of factors, many of which are outside our control. These factors include the extent to which
our AEM technology and related accessories gain market acceptance; our investments in marketing, sales, research and development and administrative
personnel necessary to support growth; our ability to expand our market share; actions of competitors; and, general economic conditions.
The market value of our common stock has dramatically fluctuated in the past and is likely to fluctuate in the future. Any of these factors,
or factors not listed, could have an immediate and significant negative impact on the market price of our stock.
Our common stock is thinly traded, the prices at
which it trades are volatile and the buying or selling actions of a few shareholders may adversely affect our stock price. As of May
31, 2023, we had a public float, which is defined as shares outstanding minus shares held by our officers, directors, or beneficial holders,
of greater than 10% of our outstanding common stock, of 7,311,381 shares, or 62% of our outstanding common stock. The average number of
shares traded in any given day over the past year has been relatively small compared to the public float. Thus, the actions of a few shareholders
either buying or selling shares of our common stock may adversely affect the price of the shares. Historically, thinly-traded securities
such as our common stock have experienced extreme price and volume fluctuations that do not necessarily relate to operating performance.
Product liability claims may exceed our current
insurance coverage. We face an inherent business risk of exposure to product liability claims in the event that the use of our products
is alleged to have resulted in adverse effects to a patient. We maintain a general liability insurance policy up to the amount of $10,000,000
that includes coverage for product liability claims. Liability claims may be excluded from the policy, may exceed the coverage limits
of the policy, or the insurance may not continue to be available on commercially reasonable terms or at all. Consequently, a product liability
claim or other claim with respect to uninsured liabilities or in excess of insured liabilities could have a material adverse effect on
our financial position, results of operations and cash flows.
We depend on certain key personnel. We are
highly dependent on a limited number of key management personnel, particularly our President and CEO, Gregory J. Trudel. Our loss of key
personnel to death, disability or termination, or our inability to hire and retain qualified personnel, could have a material adverse
effect on our financial position, results of operations and cash flow.
Any cybersecurity-related attack, significant data
breach or disruption of the information technology systems or networks on which we rely could negatively affect our business. Our
operations rely on information technology systems for the use, storage and transmission of sensitive and confidential information with
respect to our customers, suppliers, employees and other parties. A malicious cybersecurity-related attack, intrusion or disruption by
either an internal or external source or other breach of the systems on which we and our employees conduct business, could lead to unauthorized
access to, use of, loss of or unauthorized disclosure of sensitive and confidential information, disruption of our services, and resulting
regulatory enforcement actions, litigation, indemnity obligations and other possible liabilities, as well as negative publicity, which
could damage our reputation, impair sales and harm our business. Cyberattacks and other malicious internet-based activity continue to
increase. In addition to traditional computer “hackers,” malicious code (such as viruses and worms), phishing, employee theft
or misuse and denial-of-service attacks, sophisticated nation-state and nation-state supported actors now engage in attacks (including
advanced persistent threat intrusions). Despite efforts to create security barriers to such threats, it is not feasible, as a practical
matter, for us to entirely mitigate these risks. If our security measures are compromised as a result of third-party action, employee,
customer, or user error, malfeasance, stolen or fraudulently obtained log-in credentials or otherwise, our reputation would be damaged,
our data, information or intellectual property, or those of our customers, may be destroyed, stolen or otherwise compromised, our business
may be harmed and we could incur significant liability.